EP Patent

EP4604931A1 — Compositions of a dipeptidyl peptidase-iv inhibitor and an antioxidant

Assigned to Merck Sharp and Dohme LLC · Expires 2025-08-27 · 1y expired

What this patent protects

Disclosed are compositions, including pharmaceutical compositions, comprising a combination of sitagliptin, or a pharmaceutically acceptable salt and/or hydrate thereof, and an antioxidant.

USPTO Abstract

Disclosed are compositions, including pharmaceutical compositions, comprising a combination of sitagliptin, or a pharmaceutically acceptable salt and/or hydrate thereof, and an antioxidant.

Drugs covered by this patent

metformin-hydrochloride (METFORMIN HYDROCHLORIDE)

Patent Metadata

Patent number: EP4604931A1
Jurisdiction: EP
Classification: —
Expires: 2025-08-27
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.